

Antitumor Activity of the Glutaminase Inhibitor CB-839

Molecular Cancer Therapeutics

13, 890-901

DOI: [10.1158/1535-7163.mct-13-0870](https://doi.org/10.1158/1535-7163.mct-13-0870)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Redox control of glutamine utilization in cancer. <i>Cell Death and Disease</i> , 2014, 5, e1561-e1561. | 6.3 | 113 |
| 2 | Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. <i>Nature Communications</i> , 2014, 5, 4900. | 12.8 | 63 |
| 3 | Action at a Distance: Allosteric and the Development of Drugs to Target Cancer Cell Metabolism. <i>Chemistry and Biology</i> , 2014, 21, 1143-1161. | 6.0 | 39 |
| 4 | Emerging approaches to target tumor metabolism. <i>Current Opinion in Pharmacology</i> , 2014, 17, 22-29. | 3.5 | 18 |
| 5 | Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. <i>Blood</i> , 2015, 126, 1346-1356. | 1.4 | 303 |
| 6 | Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer. <i>Radiation Oncology</i> , 2015, 10, 145. | 2.7 | 47 |
| 7 | Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. <i>Clinical Pharmacology: Advances and Applications</i> , 2015, 7, 57. | 1.2 | 12 |
| 8 | Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22830-22855. | 4.1 | 118 |
| 9 | Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-13. | 1.9 | 88 |
| 10 | Glutaminolysis and autophagy in cancer. <i>Autophagy</i> , 2015, 11, 1198-1208. | 9.1 | 104 |
| 11 | The GLU that Holds Cancer Together: Targeting GLUTamine Transporters in Breast Cancer. <i>Cancer Cell</i> , 2015, 27, 317-319. | 16.8 | 13 |
| 12 | Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. <i>Endocrine-Related Cancer</i> , 2015, 22, 577-591. | 3.1 | 79 |
| 13 | Troglitazone suppresses glutamine metabolism through a PPAR-independent mechanism. <i>Biological Chemistry</i> , 2015, 396, 937-947. | 2.5 | 5 |
| 14 | Metabolic signatures of human breast cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e992217. | 0.7 | 56 |
| 15 | Seek and Destroy: Relating Cancer Drivers to Therapies. <i>Cancer Cell</i> , 2015, 27, 319-321. | 16.8 | 5 |
| 16 | Targeting glutamine metabolism in myeloproliferative neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 241-247. | 1.4 | 22 |
| 17 | Organ-Specific Cancer Metabolism and Its Potential for Therapy. <i>Handbook of Experimental Pharmacology</i> , 2015, 233, 321-353. | 1.8 | 86 |
| 18 | Metabolic Dependencies in RAS-Driven Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1828-1834. | 7.0 | 192 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5425-5430. | 7.1 | 190 |
| 20 | The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?. Acta Biochimica Et Biophysica Sinica, 2016, 48, 17-26. | 2.0 | 13 |
| 21 | Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ÅY-lapachone. Cancer & Metabolism, 2015, 3, 12. | 5.0 | 104 |
| 22 | Amino acid management in cancer. Seminars in Cell and Developmental Biology, 2015, 43, 22-32. | 5.0 | 96 |
| 23 | Research into cancer metabolomics: Towards a clinical metamorphosis. Seminars in Cell and Developmental Biology, 2015, 43, 52-64. | 5.0 | 36 |
| 24 | MYC, Metabolism, and Cancer. Cancer Discovery, 2015, 5, 1024-1039. | 9.4 | 919 |
| 25 | A motor relay on ciliary tracks. Nature Cell Biology, 2015, 17, 1517-1519. | 10.3 | 2 |
| 26 | MYC-induced reprogramming of glutamine catabolism supports optimal virus replication. Nature Communications, 2015, 6, 8873. | 12.8 | 119 |
| 27 | Rethinking glutamine addiction. Nature Cell Biology, 2015, 17, 1515-1517. | 10.3 | 30 |
| 28 | Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase. Neurochemistry International, 2015, 88, 10-14. | 3.8 | 10 |
| 29 | Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochemical and Biophysical Research Communications, 2015, 456, 452-458. | 2.1 | 82 |
| 30 | Glutamate enrichment as new diagnostic opportunity in breast cancer. International Journal of Cancer, 2015, 136, 1619-1628. | 5.1 | 103 |
| 31 | On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget, 2016, 7, 67626-67649. | 1.8 | 42 |
| 32 | Oncogenic regulation of tumor metabolic reprogramming. Oncotarget, 2016, 7, 62726-62753. | 1.8 | 116 |
| 33 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget, 2016, 7, 79722-79735. | 1.8 | 133 |
| 34 | Paracrine Induction of HIF by Glutamate in Breast Cancer: Egln1 Senses Cysteine. Cell, 2016, 166, 126-139. | 28.9 | 187 |
| 36 | Glutamine Metabolism in Gliomas. Advances in Neurobiology, 2016, 13, 259-273. | 1.8 | 7 |
| 37 | Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood, 2016, 128, 667-679. | 1.4 | 128 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 38 | Mechanistic Basis of Glutaminase Activation. <i>Journal of Biological Chemistry</i> , 2016, 291, 20900-20910. | 3.4 | 28 |
| 39 | Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells. <i>Cell Reports</i> , 2016, 17, 821-836. | 6.4 | 132 |
| 40 | Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. <i>Cell Reports</i> , 2016, 17, 876-890. | 6.4 | 54 |
| 41 | Specific Detection of Cellular Glutamine Hydrolysis in Live Cells Using HNCO Triple Resonance NMR. <i>ACS Chemical Biology</i> , 2016, 11, 3140-3145. | 3.4 | 3 |
| 42 | Expanding the view of breast cancer metabolism: Promising molecular targets and therapeutic opportunities. , 2016, 167, 60-73. | | 34 |
| 43 | From Krebs to clinic: glutamine metabolism to cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 619-634. | 28.4 | 1,367 |
| 44 | Discovery of 6-Diazo-5-oxo-<sc>l</sc>-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8621-8633. | 6.4 | 98 |
| 45 | Metabolism in Cancer. <i>Recent Results in Cancer Research</i> , 2016, , . | 1.8 | 5 |
| 46 | Novel drugs that target the metabolic reprogramming in renal cell cancer. <i>Cancer & Metabolism</i> , 2016, 4, 14. | 5.0 | 64 |
| 47 | Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5328-36. | 7.1 | 180 |
| 48 | Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. <i>Recent Results in Cancer Research</i> , 2016, 207, 157-175. | 1.8 | 25 |
| 49 | Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. <i>Nature Communications</i> , 2016, 7, 11457. | 12.8 | 386 |
| 50 | Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016, 6, 1315-1333. | 9.4 | 137 |
| 51 | The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. <i>Nature Communications</i> , 2016, 7, 11321. | 12.8 | 132 |
| 52 | Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. <i>Genes and Diseases</i> , 2016, 3, 241-243. | 3.4 | 13 |
| 53 | Cancer metabolism at a glance. <i>Journal of Cell Science</i> , 2016, 129, 3367-3373. | 2.0 | 176 |
| 55 | NQO1 Bioactivatable Drugs Enhance Radiation Responses. , 2016, , 225-252. | | 1 |
| 56 | Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. <i>Cell Metabolism</i> , 2016, 24, 685-700. | 16.2 | 293 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 57 | Oligomeric interface modulation causes misregulation of purine 5 ^Â -nucleotidase in relapsed leukemia. <i>BMC Biology</i> , 2016, 14, 91. | 3.8 | 9 |
| 58 | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress. <i>International Journal of Oncology</i> , 2016, 48, 399-408. | 3.3 | 70 |
| 59 | Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. <i>Oncogene</i> , 2016, 35, 3955-3964. | 5.9 | 76 |
| 60 | Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 520-524. | 2.8 | 50 |
| 62 | Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels. <i>Redox Biology</i> , 2016, 8, 136-148. | 9.0 | 15 |
| 63 | Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. <i>Cell Metabolism</i> , 2016, 23, 517-528. | 16.2 | 616 |
| 64 | Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. <i>Journal of Neuro-Oncology</i> , 2016, 128, 57-66. | 2.9 | 26 |
| 65 | Design and evaluation of novel glutaminase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1819-1839. | 3.0 | 50 |
| 66 | Glutaminolysis as a target for cancer therapy. <i>Oncogene</i> , 2016, 35, 3619-3625. | 5.9 | 311 |
| 67 | Clinical development of cancer therapeutics that target metabolism. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 367-372. | 0.5 | 29 |
| 68 | ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. <i>Oncogene</i> , 2016, 35, 3201-3208. | 5.9 | 430 |
| 69 | Cancer metabolism: a therapeutic perspective. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 11-31. | 27.6 | 1,028 |
| 70 | Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. <i>Cell Reports</i> , 2017, 18, 601-610. | 6.4 | 125 |
| 71 | Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective. <i>Vascular Pharmacology</i> , 2017, 90, 8-18. | 2.1 | 41 |
| 72 | Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193. | 16.8 | 532 |
| 73 | Biomolecular Interaction Assays Identified Dual Inhibitors of Glutaminase and Glutamate Dehydrogenase That Disrupt Mitochondrial Function and Prevent Growth of Cancer Cells. <i>Analytical Chemistry</i> , 2017, 89, 1689-1696. | 6.5 | 38 |
| 74 | Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1243-1246. | 2.2 | 22 |
| 75 | A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. <i>Future Medicinal Chemistry</i> , 2017, 9, 223-243. | 2.3 | 109 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 76 | Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. <i>Journal of Biological Chemistry</i> , 2017, 292, 6095-6107. | 3.4 | 21 |
| 77 | [¹⁸ F](2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. <i>Cancer Research</i> , 2017, 77, 1476-1484. | 0.9 | 75 |
| 78 | Glutamine Metabolism in Cancer: Understanding the Heterogeneity. <i>Trends in Cancer</i> , 2017, 3, 169-180. | 7.4 | 472 |
| 79 | Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 427-443. | 4.1 | 1 |
| 80 | Glutaminolysis: A Hallmark of Cancer Metabolism. <i>Annual Review of Biomedical Engineering</i> , 2017, 19, 163-194. | 12.3 | 528 |
| 81 | Glutamine Addiction In Gliomas. <i>Neurochemical Research</i> , 2017, 42, 1735-1746. | 3.3 | 64 |
| 82 | Energy metabolism in skin cancers: A therapeutic perspective. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2017, 1858, 712-722. | 1.0 | 26 |
| 83 | Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. <i>Journal of Nuclear Medicine</i> , 2017, 58, 689-696. | 5.0 | 15 |
| 84 | Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. <i>EMBO Journal</i> , 2017, 36, 1302-1315. | 7.8 | 424 |
| 85 | c-MYC mRNA tail tale about glutamine control of transcription. <i>EMBO Journal</i> , 2017, 36, 1806-1808. | 7.8 | 4 |
| 86 | Metabolic reprogramming in clear cell renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 410-419. | 9.6 | 323 |
| 87 | Hopefully devoted to Q: targeting glutamine addiction in cancer. <i>British Journal of Cancer</i> , 2017, 116, 1375-1381. | 6.4 | 93 |
| 88 | Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. <i>Cancer Letters</i> , 2017, 388, 54-63. | 7.2 | 32 |
| 89 | From Prokaryotes to Cancer: Glutamine Flux in Multicellular Units. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 637-644. | 7.1 | 16 |
| 90 | Division enzyme regulates metabolism. <i>Nature</i> , 2017, 546, 357-358. | 27.8 | 28 |
| 91 | Multifaceted Roles of Glutathione and Glutathione-Based Systems in Carcinogenesis and Anticancer Drug Resistance. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1217-1234. | 5.4 | 79 |
| 92 | Patent highlights December 2016–January 2017. <i>Pharmaceutical Patent Analyst</i> , 2017, 6, 97-104. | 1.1 | 1 |
| 93 | Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 669-686. | 8.7 | 155 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 94 | Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5599-5612. | 6.4 | 30 |
| 95 | How to suck like an octopus. <i>Nature</i> , 2017, 546, 358-359. | 27.8 | 15 |
| 96 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 79-92. | 28.4 | 686 |
| 97 | Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma. <i>BBA Clinical</i> , 2017, 7, 8-15. | 4.1 | 24 |
| 98 | Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. <i>Carcinogenesis</i> , 2017, 38, bgw205. | 2.8 | 56 |
| 99 | Contrasting effects of glutamine deprivation on apoptosis induced by conventionally used anticancer drugs. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 498-506. | 4.1 | 15 |
| 100 | Targeting amino acid metabolism for cancer therapy. <i>Drug Discovery Today</i> , 2017, 22, 796-804. | 6.4 | 215 |
| 101 | Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 3117-3123. | 1.8 | 40 |
| 102 | <i>De novo</i> MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition. <i>Molecular Systems Biology</i> , 2017, 13, 940. | 7.2 | 43 |
| 103 | Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging. <i>Cancer Research</i> , 2017, 77, 6746-6758. | 0.9 | 85 |
| 104 | Targeting Metabolism for Cancer Therapy. <i>Cell Chemical Biology</i> , 2017, 24, 1161-1180. | 5.2 | 677 |
| 105 | Downregulation of SIRT2 Inhibits Invasion of Hepatocellular Carcinoma by Inhibiting Energy Metabolism. <i>Translational Oncology</i> , 2017, 10, 917-927. | 3.7 | 43 |
| 106 | Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. <i>BioDrugs</i> , 2017, 31, 379-392. | 4.6 | 8 |
| 107 | Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. <i>Clinical Cancer Research</i> , 2017, 23, 6292-6304. | 7.0 | 69 |
| 108 | Deciphering metabolic rewiring in breast cancer subtypes. <i>Translational Research</i> , 2017, 189, 105-122. | 5.0 | 45 |
| 109 | ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. <i>Oncogenesis</i> , 2017, 6, e367-e367. | 4.9 | 57 |
| 110 | The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. <i>Science Signaling</i> , 2017, 10, . | 3.6 | 80 |
| 111 | Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. <i>Scientific Reports</i> , 2017, 7, 16159. | 3.3 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 112 | Brachyantheraoid A ₈ , a new natural nor-oleanane triterpenoid as a kidney-type glutaminase inhibitor from <i>Stauntonia brachyanthera</i> . RSC Advances, 2017, 7, 52533-52542. | 3.6 | 7 |
| 113 | Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nature Communications, 2017, 8, 15965. | 12.8 | 231 |
| 114 | Nature and Nurture: What Determines Tumor Metabolic Phenotypes?. Cancer Research, 2017, 77, 3131-3134. | 0.9 | 60 |
| 115 | Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO Journal, 2017, 36, 2334-2352. | 7.8 | 195 |
| 116 | Bioluminescent Assays for Glucose and Glutamine Metabolism: High-Throughput Screening for Changes in Extracellular and Intracellular Metabolites. SLAS Discovery, 2017, 22, 366-377. | 2.7 | 14 |
| 117 | Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo. Molecular Imaging and Biology, 2017, 19, 421-428. | 2.6 | 17 |
| 118 | Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene, 2017, 36, 1991-2001. | 5.9 | 54 |
| 119 | Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology, 2017, 65, 789-803. | 7.3 | 48 |
| 120 | Search for Inhibitors of Ras-Driven Cancers. , 2017, , 135-154. | | 1 |
| 121 | Targeting Metabolic Vulnerabilities in RAS-Mutant Cells. , 2017, , 193-212. | | 1 |
| 122 | Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism. Open Biology, 2017, 7, 170219. | 3.6 | 98 |
| 123 | Red blood cells in hemorrhagic shock: a critical role for glutaminolysis in fueling alanine transamination in rats. Blood Advances, 2017, 1, 1296-1305. | 5.2 | 28 |
| 124 | Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer. Frontiers in Physiology, 2017, 8, 217. | 2.8 | 47 |
| 125 | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2017, 6, 43. | 2.4 | 40 |
| 126 | Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. Metabolites, 2017, 7, 18. | 2.9 | 35 |
| 127 | MYC-Driven Pathways in Breast Cancer Subtypes. Biomolecules, 2017, 7, 53. | 4.0 | 152 |
| 128 | Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Frontiers in Oncology, 2017, 7, 40. | 2.8 | 101 |
| 129 | Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. ELife, 2017, 6, . | 6.0 | 237 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 130 | Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1456-1465. | 1.7 | 7 |
| 131 | Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. <i>PLoS ONE</i> , 2017, 12, e0185092. | 2.5 | 114 |
| 132 | Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. <i>PLoS ONE</i> , 2017, 12, e0182679. | 2.5 | 40 |
| 133 | Drug-induced amino acid deprivation as strategy for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 144. | 17.0 | 117 |
| 134 | Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 825-832. | 3.8 | 25 |
| 135 | Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. <i>Oncotarget</i> , 2017, 8, 35863-35876. | 1.8 | 94 |
| 136 | Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. <i>Blood</i> , 2018, 131, 1639-1653. | 1.4 | 114 |
| 137 | Phosphorylation of glutaminase by PKC μ is essential for its enzymatic activity and critically contributes to tumorigenesis. <i>Cell Research</i> , 2018, 28, 655-669. | 12.0 | 51 |
| 138 | Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. <i>EMBO Reports</i> , 2018, 19, . | 4.5 | 70 |
| 139 | Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. <i>Cell Chemical Biology</i> , 2018, 25, 705-717.e11. | 5.2 | 79 |
| 140 | Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6136-6145. | 2.6 | 47 |
| 141 | In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018, 287, 667-675. | 7.3 | 80 |
| 142 | Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 205. | 6.3 | 22 |
| 143 | Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner. <i>Nature Communications</i> , 2018, 9, 545. | 12.8 | 114 |
| 145 | Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1343-1353. | 0.7 | 21 |
| 146 | Expression of the glutamine metabolism-related proteins glutaminase 1 and glutamate dehydrogenase in canine mammary tumours. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 239-245. | 1.8 | 5 |
| 147 | Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. <i>Journal of Biological Chemistry</i> , 2018, 293, 3535-3545. | 3.4 | 70 |
| 148 | Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. <i>Nature Medicine</i> , 2018, 24, 194-202. | 30.7 | 303 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 149 | Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. <i>Cancer Discovery</i> , 2018, 8, 276-287. | 9.4 | 248 |
| 150 | Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate. <i>Journal of Neuroinflammation</i> , 2018, 15, 79. | 7.2 | 32 |
| 151 | Caudatan A, an undescribed human kidney-type glutaminase inhibitor with tetracyclic flavan from <i>Ohwia caudata</i> . <i>Phytochemistry</i> , 2018, 152, 22-28. | 2.9 | 9 |
| 152 | Metabolomics and Metabolic Reprogramming in Kidney Cancer. <i>Seminars in Nephrology</i> , 2018, 38, 175-182. | 1.6 | 66 |
| 153 | Dual targeting of EGFR and glutaminase in lung cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1297883. | 0.7 | 1 |
| 154 | Glutaminolysis Promotes Collagen Translation and Stability via α -Ketoglutarate-mediated mTOR Activation and Proline Hydroxylation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 378-390. | 2.9 | 92 |
| 155 | Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 264-275. | 4.1 | 43 |
| 156 | MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 258-265. | 6.4 | 74 |
| 157 | Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. <i>Trends in Cell Biology</i> , 2018, 28, 201-212. | 7.9 | 94 |
| 158 | Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. <i>Histopathology</i> , 2018, 72, 183-190. | 2.9 | 60 |
| 159 | Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2018, 8, 556. | 2.8 | 67 |
| 160 | Therapeutic strategies to target RAS-mutant cancers. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 709-720. | 27.6 | 274 |
| 161 | Glutaminase inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 823-835. | 5.0 | 23 |
| 162 | Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1855-F1868. | 2.7 | 28 |
| 163 | Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 211. | 8.6 | 99 |
| 164 | Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. <i>Cell</i> , 2018, 175, 101-116.e25. | 28.9 | 234 |
| 165 | We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1824-1832. | 4.1 | 148 |
| 166 | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 284. | 2.8 | 80 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 167 | Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. <i>Cancer Letters</i> , 2018, 430, 133-147. | 7.2 | 54 |
| 168 | Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. <i>Journal of Molecular Medicine</i> , 2018, 96, 777-790. | 3.9 | 26 |
| 169 | The Heterogeneity of Cancer Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2018, , . | 1.6 | 7 |
| 170 | Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 93-147. | 3.2 | 8 |
| 171 | Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. <i>Cell Metabolism</i> , 2018, 28, 383-399.e9. | 16.2 | 62 |
| 172 | Glutamine Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 13-32. | 1.6 | 153 |
| 173 | Cancer Metabolism: Current Understanding and Therapies. <i>Chemical Reviews</i> , 2018, 118, 6893-6923. | 47.7 | 161 |
| 174 | Interplay between ShcA Signaling and PGC-1 β Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4826-4838. | 0.9 | 10 |
| 175 | Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. <i>Current Opinion in Oncology</i> , 2018, 30, 338-344. | 2.4 | 7 |
| 176 | Emerging roles of Myc in stem cell biology and novel tumor therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 173. | 8.6 | 189 |
| 177 | Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2018, 18, 494-504. | 2.1 | 180 |
| 178 | Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5521-5526. | 0.9 | 19 |
| 179 | PET Imaging of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients. <i>Molecular Pharmaceutics</i> , 2018, 15, 3448-3455. | 4.6 | 18 |
| 180 | Oligodendroglioma Cells Lack Glutamine Synthetase and Are Auxotrophic for Glutamine, but Do not Depend on Glutamine Anaplerosis for Growth. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1099. | 4.1 | 20 |
| 181 | Flexibility in metabolism bestows tenacious viability on cancer. <i>Life Sciences</i> , 2018, 208, 20-25. | 4.3 | 4 |
| 182 | Amino Acid Transporters and Glutamine Metabolism in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 907. | 4.1 | 103 |
| 183 | The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 67-75. | 7.4 | 93 |
| 184 | Asparagine, a critical limiting metabolite during glutamine starvation. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1441633. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 185 | Targeting Glutamine Metabolism for Cancer Treatment. <i>Biomolecules and Therapeutics</i> , 2018, 26, 19-28. | 2.4 | 218 |
| 186 | Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells. <i>Biochemical Pharmacology</i> , 2018, 156, 204-214. | 4.4 | 30 |
| 187 | Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6433-6446. | 7.0 | 54 |
| 188 | A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3. <i>Cell Metabolism</i> , 2018, 28, 721-736.e6. | 16.2 | 159 |
| 189 | Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting. <i>Cell Metabolism</i> , 2018, 28, 706-720.e6. | 16.2 | 132 |
| 190 | Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment. <i>Cell Death Discovery</i> , 2018, 4, 24. | 4.7 | 15 |
| 191 | Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, . | 2.4 | 96 |
| 192 | Deciphering T Cell Immunometabolism with Activity-Based Protein Profiling. <i>Current Topics in Microbiology and Immunology</i> , 2018, 420, 175-210. | 1.1 | 2 |
| 193 | EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. <i>Molecular Carcinogenesis</i> , 2018, 57, 1342-1357. | 2.7 | 40 |
| 194 | Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target. <i>Medicinal Research Reviews</i> , 2019, 39, 70-113. | 10.5 | 65 |
| 195 | Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 46-59. | 6.4 | 41 |
| 196 | Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1096-1115. | 6.4 | 77 |
| 197 | Targeting metabolism to regulate immune responses in autoimmunity and cancer. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 669-688. | 46.4 | 176 |
| 198 | Metabolic Plasticity of Acute Myeloid Leukemia. <i>Cells</i> , 2019, 8, 805. | 4.1 | 103 |
| 199 | Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 686. | 2.8 | 41 |
| 200 | Metabolic Regulation of Redox Balance in Cancer. <i>Cancers</i> , 2019, 11, 955. | 3.7 | 80 |
| 201 | Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth. <i>Cell Chemical Biology</i> , 2019, 26, 1214-1228.e25. | 5.2 | 97 |
| 202 | Inhibition of Anaplerotic Glutaminolysis Underlies Selenite Toxicity in Human Lung Cancer. <i>Proteomics</i> , 2019, 19, e1800486. | 2.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 203 | Design and synthesis of biotinylated Hexylselen as a probe to identify KGA allosteric inhibitors by a convenient biomolecular interaction assay. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2498-2502. | 2.2 | 2 |
| 204 | Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9642-9657. | 6.4 | 19 |
| 205 | UGCG influences glutamine metabolism of breast cancer cells. <i>Scientific Reports</i> , 2019, 9, 15665. | 3.3 | 23 |
| 206 | eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5151. | 12.8 | 64 |
| 207 | Fifty Shades of α -Ketoglutarate on Cellular Programming. <i>Molecular Cell</i> , 2019, 76, 1-3. | 9.7 | 29 |
| 208 | Glutamine Metabolism in Brain Tumors. <i>Cancers</i> , 2019, 11, 1628. | 3.7 | 53 |
| 209 | An Improved Indicator System for Evaluating the Progress of Sustainable Development Goals (SDGs) Sub-Target 9.1 in County Level. <i>Sustainability</i> , 2019, 11, 4783. | 3.2 | 12 |
| 210 | Modern Perspective on Metabolic Reprogramming in Malignant Neoplasms. <i>Biochemistry (Moscow)</i> , 2019, 84, 1129-1142. | 1.5 | 14 |
| 211 | Inhibition of cancer metabolism: a patent landscape. <i>Pharmaceutical Patent Analyst</i> , 2019, 8, 117-138. | 1.1 | 4 |
| 212 | Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 771-785. | 4.1 | 9 |
| 213 | Maintaining cytosolic aspartate levels is a major function of the TCA cycle in proliferating cells. <i>Molecular and Cellular Oncology</i> , 2019, 6, e1536843. | 0.7 | 19 |
| 214 | Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. <i>Cell Communication and Signaling</i> , 2019, 17, 99. | 6.5 | 46 |
| 215 | The Emerging Role of l-Glutamine in Cardiovascular Health and Disease. <i>Nutrients</i> , 2019, 11, 2092. | 4.1 | 85 |
| 216 | Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1937-1946. | 4.1 | 19 |
| 217 | Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. <i>Cell Reports</i> , 2019, 29, 76-88.e7. | 6.4 | 66 |
| 218 | Warburg and Krebs and related effects in cancer. <i>Expert Reviews in Molecular Medicine</i> , 2019, 21, e4. | 3.9 | 22 |
| 219 | Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions. <i>Journal of the American Chemical Society</i> , 2019, 141, 17117-17124. | 13.7 | 41 |
| 220 | <p>Effect of glutaminase inhibition on cancer-induced bone pain</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 273-282. | 1.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 221 | Physapubescin I from husk tomato suppresses SW1990 cancer cell growth by targeting kidney-type glutaminase. <i>Bioorganic Chemistry</i> , 2019, 92, 103186. | 4.1 | 16 |
| 222 | Mitochondrial calcium exchange links metabolism with the epigenome to control cellular differentiation. <i>Nature Communications</i> , 2019, 10, 4509. | 12.8 | 93 |
| 223 | Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936. | 7.0 | 22 |
| 224 | Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2+/+ Mice. <i>Neoplasia</i> , 2019, 21, 230-238. | 5.3 | 13 |
| 225 | Targeting Metabolic Redox Circuits for Cancer Therapy. <i>Trends in Biochemical Sciences</i> , 2019, 44, 401-414. | 7.5 | 138 |
| 226 | Recombinant L-glutaminase obtained from <i>Geobacillus thermodenitrificans</i> DSM-465: characterization and in silico elucidation of conserved structural domains. <i>RSC Advances</i> , 2019, 9, 4258-4267. | 3.6 | 2 |
| 227 | Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer. <i>Bioscience Reports</i> , 2019, 39, . | 2.4 | 40 |
| 228 | Inhibition of ERK1/2 Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. <i>Cell Reports</i> , 2019, 27, 3587-3601.e4. | 6.4 | 29 |
| 229 | Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?. <i>Cancers</i> , 2019, 11, 804. | 3.7 | 75 |
| 230 | The Pleiotropic Effects of Glutamine Metabolism in Cancer. <i>Cancers</i> , 2019, 11, 770. | 3.7 | 89 |
| 231 | Can Metabolic Pathways Be Therapeutic Targets in Rheumatoid Arthritis?. <i>Journal of Clinical Medicine</i> , 2019, 8, 753. | 2.4 | 32 |
| 232 | Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1374-1385. | 4.1 | 26 |
| 233 | Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6540-6560. | 6.4 | 21 |
| 234 | Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity. <i>Cells</i> , 2019, 8, 401. | 4.1 | 51 |
| 235 | Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 211-224. | 3.3 | 11 |
| 236 | Novel Therapeutics Affecting Metabolic Pathways. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e79-e87. | 3.8 | 9 |
| 237 | Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 61. | 5.0 | 42 |
| 238 | The Diverse Functions of Non-Essential Amino Acids in Cancer. <i>Cancers</i> , 2019, 11, 675. | 3.7 | 119 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 239 | Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253. | 5.0 | 30 |
| 240 | GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3 β /CyclinD1 pathway. <i>Experimental Cell Research</i> , 2019, 381, 1-9. | 2.6 | 32 |
| 241 | The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 511-524. | 3.4 | 19 |
| 242 | Role of Metabolic Reprogramming in Epithelial to Mesenchymal Transition (EMT). <i>International Journal of Molecular Sciences</i> , 2019, 20, 2042. | 4.1 | 93 |
| 243 | LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. <i>Cancer Research</i> , 2019, 79, 3251-3267. | 0.9 | 196 |
| 244 | Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 9342-9357. | 3.4 | 53 |
| 245 | Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma. <i>Cancer Research</i> , 2019, 79, 1799-1809. | 0.9 | 29 |
| 246 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 425-441. | 27.6 | 452 |
| 247 | Multimiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 355. | 2.4 | 60 |
| 248 | Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 4079-4090. | 7.0 | 113 |
| 249 | The "Achilles Heel" of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy. <i>Kidney Cancer</i> , 2019, 3, 15-29. | 0.4 | 50 |
| 250 | AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3604-3613. | 7.1 | 96 |
| 251 | Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism. <i>Oncogene</i> , 2019, 38, 4729-4738. | 5.9 | 47 |
| 252 | Metabolic Pathways Fueling the Endothelial Cell Drive. <i>Annual Review of Physiology</i> , 2019, 81, 483-503. | 13.1 | 91 |
| 253 | CirHMGCS1 Promotes Hepatoblastoma Cell Proliferation by Regulating the IGF Signaling Pathway and Glutaminolysis. <i>Theranostics</i> , 2019, 9, 900-919. | 10.0 | 60 |
| 254 | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 91-98. | 1.2 | 6 |
| 255 | Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress. <i>Cancer Research</i> , 2019, 79, 5849-5859. | 0.9 | 26 |
| 256 | Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 773. | 3.5 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 257 | The progress and development of GLUT1 inhibitors targeting cancer energy metabolism. <i>Future Medicinal Chemistry</i> , 2019, 11, 2333-2352. | 2.3 | 43 |
| 258 | Amino Acid-Mediated Metabolism: A New Power to Influence Properties of Stem Cells. <i>Stem Cells International</i> , 2019, 2019, 1-9. | 2.5 | 8 |
| 259 | Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions. <i>Anticancer Research</i> , 2019, 39, 6723-6730. | 1.1 | 16 |
| 260 | Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. <i>Scientific Reports</i> , 2019, 9, 19180. | 3.3 | 37 |
| 261 | Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 940. | 6.3 | 23 |
| 262 | The tumor microenvironment in renal cell cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 194-199. | 2.4 | 36 |
| 263 | GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay. <i>Human Molecular Genetics</i> , 2019, 28, 96-104. | 2.9 | 23 |
| 264 | A unique metabolic dependency for liver cancer stem cells. <i>EBioMedicine</i> , 2019, 39, 9-10. | 6.1 | 4 |
| 265 | Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. <i>International Journal of Radiation Biology</i> , 2019, 95, 436-442. | 1.8 | 77 |
| 266 | Immunological and Genetic Biomarkers of Sarcomas. , 2019, , 591-608. | | 0 |
| 267 | THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 814-822. | 6.1 | 31 |
| 268 | Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. <i>Haematologica</i> , 2019, 104, 1016-1025. | 3.5 | 14 |
| 269 | Glutamate dehydrogenase (GLUD1) expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 79-91. | 2.5 | 32 |
| 270 | Crosstalk between Estrogen Signaling and Breast Cancer Metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 25-38. | 7.1 | 93 |
| 271 | Functional Proteomics of Breast Cancer Metabolism Identifies GLUL as Responder during Hypoxic Adaptation. <i>Journal of Proteome Research</i> , 2019, 18, 1352-1362. | 3.7 | 9 |
| 272 | Kidney-Type Glutaminase Inhibitor Hexylselen Selectively Kills Cancer Cells via a Three-Pronged Mechanism. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 18-30. | 4.9 | 19 |
| 273 | Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents. <i>Haematologica</i> , 2019, 104, 806-818. | 3.5 | 44 |
| 274 | Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog β -mutant colorectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1106-1121. | 2.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 275 | Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. <i>Cancer Reports</i> , 2019, 2, e1131. | 1.4 | 8 |
| 276 | Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 589-603. | 6.4 | 64 |
| 277 | iTRAQ-Based Quantitative Proteomics Approach Identifies Novel Diagnostic Biomarkers That Were Essential for Glutamine Metabolism and Redox Homeostasis for Gastric Cancer. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800038. | 1.6 | 22 |
| 278 | Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy. <i>Cell Metabolism</i> , 2019, 29, 124-140.e10. | 16.2 | 232 |
| 279 | Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction. <i>Schizophrenia Bulletin</i> , 2019, 45, 127-137. | 4.3 | 26 |
| 280 | Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 34-43. | 5.0 | 84 |
| 281 | <i>Cancer Metabolism</i> , 2020, , 127-138.e4. | | 3 |
| 282 | GLS2 is protumorigenic in breast cancers. <i>Oncogene</i> , 2020, 39, 690-702. | 5.9 | 35 |
| 283 | Small-Molecule Inhibition of Glucose Transporters GLUT1. <i>ChemBioChem</i> , 2020, 21, 45-52. | 2.6 | 59 |
| 284 | The role of glutaminase in cancer. <i>Histopathology</i> , 2020, 76, 498-508. | 2.9 | 101 |
| 285 | Pharmacokinetic Assessment of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine in Patients with Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 357-366. | 5.0 | 23 |
| 286 | Oxidative Stress and Cancer Development: Are Noncoding RNAs the Missing Links?. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 1209-1229. | 5.4 | 32 |
| 287 | Targeting Cell Metabolism as Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 285-308. | 5.4 | 32 |
| 288 | Metabolic fingerprinting reveals extensive consequences of GLS hyperactivity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129484. | 2.4 | 3 |
| 289 | TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 68. | 3.7 | 57 |
| 290 | The Warburg Effect 97 Years after Its Discovery. <i>Cancers</i> , 2020, 12, 2819. | 3.7 | 153 |
| 291 | Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors as revealed by metabolic connectivity profiling. <i>Cancer & Metabolism</i> , 2020, 8, 22. | 5.0 | 10 |
| 292 | Manipulation of Glucose Availability to Boost Cancer Immunotherapies. <i>Cancers</i> , 2020, 12, 2940. | 3.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 293 | Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. <i>Cells</i> , 2020, 9, 2308. | 4.1 | 211 |
| 294 | The emerging role of targeting cancer metabolism for cancer therapy. <i>Tumor Biology</i> , 2020, 42, 101042832096528. | 1.8 | 48 |
| 295 | Targeting Metabolic Pathways in Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 407-418. | 2.0 | 6 |
| 296 | Glutamine Metabolism Controls Stem Cell Fate Reversibility and Long-Term Maintenance in the Hair Follicle. <i>Cell Metabolism</i> , 2020, 32, 629-642.e8. | 16.2 | 60 |
| 297 | Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 1117-1127. | 4.4 | 3 |
| 298 | Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. <i>Translational Oncology</i> , 2020, 13, 100828. | 3.7 | 25 |
| 299 | STAT1 upregulates glutaminase and modulates amino acids and glutathione metabolism. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 672-677. | 2.1 | 3 |
| 300 | Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 124. | 17.1 | 169 |
| 301 | Simultaneous Induction of Glycolysis and Oxidative Phosphorylation during Activation of Hepatic Stellate Cells Reveals Novel Mitochondrial Targets to Treat Liver Fibrosis. <i>Cells</i> , 2020, 9, 2456. | 4.1 | 25 |
| 302 | <p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 273-288. | 5.8 | 9 |
| 303 | Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8993. | 4.1 | 9 |
| 304 | A second Warburg-like effect in cancer metabolism: The metabolic shift of glutamine-derived nitrogen. <i>BioEssays</i> , 2020, 42, e2000169. | 2.5 | 25 |
| 305 | Targeting Glutamine Metabolism and PD-L1: A Novel Anti-tumor Pas de Deux. <i>Molecular Cell</i> , 2020, 80, 555-557. | 9.7 | 4 |
| 306 | Circular RNA circGSK3B Promotes Cell Proliferation, Migration, and Invasion by Sponging miR-1265 and Regulating CAB39 Expression in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 598256. | 2.8 | 12 |
| 307 | Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115698. | 3.0 | 6 |
| 308 | Synthesis of Î±-Ketoglutaramic acid. <i>Analytical Biochemistry</i> , 2020, 607, 113862. | 2.4 | 7 |
| 309 | Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. <i>Cells</i> , 2020, 9, 1766. | 4.1 | 19 |
| 310 | SIRT7-mediated modulation of glutaminase 1 regulates TGFÎ²-induced pulmonary fibrosis. <i>FASEB Journal</i> , 2020, 34, 8920-8940. | 0.5 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 311 | Upregulation of GLS1 Isoforms KGA and GAC Facilitates Mitochondrial Metabolism and Cell Proliferation in Epstein-Barr Virus Infected Cells. <i>Viruses</i> , 2020, 12, 811. | 3.3 | 13 |
| 312 | Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model. <i>Cancer & Metabolism</i> , 2020, 8, 9. | 5.0 | 22 |
| 313 | Targeting Tumor Metabolism to Overcome Radioresistance. <i>Cancer Drug Discovery and Development</i> , 2020, , 219-263. | 0.4 | 2 |
| 314 | Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2465-2475. | 4.1 | 25 |
| 315 | Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580617. | 2.8 | 44 |
| 316 | Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway. <i>Cancer Research</i> , 2020, 80, 5478-5490. | 0.9 | 14 |
| 317 | Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 589508. | 2.8 | 86 |
| 318 | Role of Protein Kinase CK2 in Aberrant Lipid Metabolism in Cancer. <i>Pharmaceuticals</i> , 2020, 13, 292. | 3.8 | 13 |
| 319 | Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12957-12977. | 6.4 | 48 |
| 320 | Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. <i>Cancer & Metabolism</i> , 2020, 8, 23. | 5.0 | 14 |
| 321 | Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4831. | 3.8 | 69 |
| 322 | Metabolic reprogramming of tumor-associated macrophages. <i>Annals of Translational Medicine</i> , 2020, 8, 1030-1030. | 1.7 | 55 |
| 323 | Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer. <i>Cancers</i> , 2020, 12, 2624. | 3.7 | 23 |
| 324 | The Role of Pi, Glutamine and the Essential Amino Acids in Modulating the Metabolism in Diabetes and Cancer. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1731-1775. | 1.9 | 6 |
| 325 | Targeting Lipid Metabolism in Liver Cancer. <i>Biochemistry</i> , 2020, 59, 3951-3964. | 2.5 | 57 |
| 326 | Glutamine reliance in cell metabolism. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1496-1516. | 7.7 | 391 |
| 327 | Thiadiazole derivatives as anticancer agents. <i>Pharmacological Reports</i> , 2020, 72, 1079-1100. | 3.3 | 49 |
| 328 | 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. <i>Cancer Research</i> , 2020, 80, 4815-4827. | 0.9 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 331 | Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment. International Journal of Molecular Sciences, 2020, 21, 6014. | 4.1 | 43 |
| 332 | Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism. Journal of Nuclear Medicine, 2020, 62, jnumed.120.250977. | 5.0 | 15 |
| 333 | Metabolic Targeting of Cancer Stem Cells. Frontiers in Oncology, 2020, 10, 537930. | 2.8 | 23 |
| 334 | NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. International Journal of Biological Sciences, 2020, 16, 3100-3115. | 6.4 | 13 |
| 335 | Cell Growth Measurement. , 0, , . | | 2 |
| 336 | Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition. Cancers, 2020, 12, 1097. | 3.7 | 9 |
| 337 | The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment. Journal of Nanomaterials, 2020, 2020, 1-13. | 2.7 | 2 |
| 338 | Metabolic reprogramming in triple-negative breast cancer. Cancer Biology and Medicine, 2020, 17, 44-59. | 3.0 | 78 |
| 339 | Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. Theranostics, 2020, 10, 6411-6429. | 10.0 | 29 |
| 340 | Mitochondria Targeting as an Effective Strategy for Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 3363. | 4.1 | 131 |
| 341 | Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer. International Journal of Molecular Sciences, 2020, 21, 3412. | 4.1 | 50 |
| 342 | Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer, 2020, 20, 470. | 2.6 | 21 |
| 343 | BPTES inhibits anthrax lethal toxin-induced inflammatory response. International Immunopharmacology, 2020, 85, 106664. | 3.8 | 4 |
| 344 | Targeting the polyamine pathway means to overcome chemoresistance in triple-negative breast cancer. Journal of Biological Chemistry, 2020, 295, 6278-6279. | 3.4 | 4 |
| 345 | Metabolic and OXPHOS Activities Quantified by Temporal ex vivo Analysis Display Patient-Specific Metabolic Vulnerabilities in Human Breast Cancers. Frontiers in Oncology, 2020, 10, 1053. | 2.8 | 4 |
| 346 | A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues. Journal of Genetics and Genomics, 2020, 47, 389-395. | 3.9 | 4 |
| 347 | Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy. Frontiers in Oncology, 2020, 10, 792. | 2.8 | 24 |
| 348 | A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nature Communications, 2020, 11, 1320. | 12.8 | 141 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 349 | Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma. <i>Cancer & Metabolism</i> , 2020, 8, 4. | 5.0 | 69 |
| 350 | Exercise-Mediated Lowering of Glutamine Availability Suppresses Tumor Growth and Attenuates Muscle Wasting. <i>IScience</i> , 2020, 23, 100978. | 4.1 | 10 |
| 351 | Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. <i>Journal of Biological Chemistry</i> , 2020, 295, 6263-6277. | 3.4 | 38 |
| 352 | Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 676-685. | 4.1 | 26 |
| 353 | Metabolic Plasticity in Chemotherapy Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 281. | 2.8 | 106 |
| 354 | Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo. <i>Metabolites</i> , 2020, 10, 268. | 2.9 | 19 |
| 355 | Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities. <i>Cancers</i> , 2020, 12, 1731. | 3.7 | 37 |
| 356 | Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism. <i>BMC Cancer</i> , 2020, 20, 617. | 2.6 | 4 |
| 357 | Metabolism of immune cells in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 516-531. | 28.4 | 407 |
| 358 | Solute carrier proteins and c-Myc: a strong connection in cancer progression. <i>Drug Discovery Today</i> , 2020, 25, 891-900. | 6.4 | 28 |
| 359 | Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020, 31, 605-622.e10. | 16.2 | 68 |
| 360 | Tumour metabolism and its unique properties in prostate adenocarcinoma. <i>Nature Reviews Urology</i> , 2020, 17, 214-231. | 3.8 | 88 |
| 361 | Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. <i>Cancer Cell</i> , 2020, 37, 147-156. | 16.8 | 233 |
| 362 | Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 2857-2869. | 3.6 | 51 |
| 364 | Targeting glutamine metabolism slows soft tissue sarcoma growth. <i>Nature Communications</i> , 2020, 11, 498. | 12.8 | 63 |
| 365 | Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer. <i>Acta Biomaterialia</i> , 2020, 105, 239-252. | 8.3 | 29 |
| 366 | Amino acids in cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 15-30. | 7.7 | 424 |
| 367 | The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled. <i>Journal of Biological Chemistry</i> , 2020, 295, 1328-1337. | 3.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 368 | l-asparaginase and 6-diazo-5-oxo-l-norleucine synergistically inhibit the growth of glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 2020, 146, 469-475. | 2.9 | 10 |
| 369 | Identification of Metabolic Alterations in Breast Cancer Using Mass Spectrometry-Based Metabolomic Analysis. <i>Metabolites</i> , 2020, 10, 170. | 2.9 | 16 |
| 370 | The EZMTT cell proliferation assay provides precise measurement for drug combinations and better correlation between in vitro and in vivo efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127134. | 2.2 | 2 |
| 371 | Radiosynthesis, in vitro and preliminary in vivo evaluation of the novel glutamine derived PET tracers [18F]fluorophenylglutamine and [18F]fluorobiphenylglutamine. <i>Nuclear Medicine and Biology</i> , 2020, 86-87, 20-29. | 0.6 | 5 |
| 372 | <p>The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2433-2447. | 2.0 | 10 |
| 373 | Metabolic Reprogramming in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 428. | 2.8 | 137 |
| 374 | Non-Coding RNAs as Key Regulators of Glutaminolysis in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2872. | 4.1 | 21 |
| 375 | A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. <i>Cell Death Discovery</i> , 2020, 6, 20. | 4.7 | 58 |
| 376 | Hypoxia Suppresses Cysteine Deprivation-induced Cell Death Via ATF4 Regulation in MDA-MB-231 Breast Cancer Cells. <i>Anticancer Research</i> , 2020, 40, 1387-1394. | 1.1 | 1 |
| 377 | Amino Acid Oncometabolism and Immunomodulation of the Tumor Microenvironment in Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 276. | 2.8 | 23 |
| 378 | Molecular modeling and LC-MS-based metabolomics of a glutamine-valproic acid (Gln-VPA) derivative on HeLa cells. <i>Molecular Diversity</i> , 2021, 25, 1077-1089. | 3.9 | 0 |
| 379 | Moonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 979-1003. | 5.4 | 13 |
| 380 | Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. <i>Translational Oncology</i> , 2021, 14, 100920. | 3.7 | 21 |
| 381 | Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112980. | 5.5 | 13 |
| 382 | Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659. | 3.0 | 8 |
| 383 | Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 494-505. | 6.4 | 62 |
| 384 | NRF2 in human neoplasm: Cancer biology and potential therapeutic target. , 2021, 217, 107664. | | 29 |
| 385 | Critical role of glutamine metabolism in cardiomyocytes under oxidative stress. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 687-693. | 2.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 386 | Cancer cell metabolism: Rewiring the mitochondrial hub. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166016. | 3.8 | 33 |
| 387 | Glutaminase in microglia: A novel regulator of neuroinflammation. <i>Brain, Behavior, and Immunity</i> , 2021, 92, 139-156. | 4.1 | 30 |
| 388 | Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion. <i>Cancer Research</i> , 2021, 81, 438-451. | 0.9 | 35 |
| 389 | The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89. | 9.6 | 87 |
| 390 | Altered glutamine metabolism in platinum resistant ovarian cancer. <i>Oncotarget</i> , 0, 7, 41637-41649. | 1.8 | 65 |
| 391 | Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. <i>Oncoimmunology</i> , 2021, 10, 1898753. | 4.6 | 28 |
| 392 | Tumor starvation by deprivation of glutamine and aspartate. , 2021, , 191-218. | | 0 |
| 393 | Diseases & Disorders Therapies Targeting Glutamine Addiction in Cancer. , 2021, , 452-461. | | 3 |
| 394 | Targeting the Prolineâ€“Glutamineâ€“Asparagineâ€“Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy. <i>Pharmaceuticals</i> , 2021, 14, 72. | 3.8 | 28 |
| 395 | Glutamine Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 17-38. | 1.6 | 43 |
| 396 | The Intricate Metabolism of Pancreatic Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 77-88. | 1.6 | 5 |
| 397 | Analysis of Melanoma Cell Glutamine Metabolism by Stable Isotope Tracing and Gas Chromatography-Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2021, 2265, 91-110. | 0.9 | 4 |
| 398 | Abrogating <sc>GPT2</sc> in tripleâ€“negative breast cancer inhibits tumor growth and promotes autophagy. <i>International Journal of Cancer</i> , 2021, 148, 1993-2009. | 5.1 | 14 |
| 399 | Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1258. | 4.1 | 18 |
| 400 | Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. <i>Theranostics</i> , 2021, 11, 8464-8479. | 10.0 | 35 |
| 401 | Glutamine metabolism in prostate cancer. , 2021, , 241-270. | | 0 |
| 402 | Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. <i>Nature Cancer</i> , 2021, 2, 189-200. | 13.2 | 36 |
| 403 | Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5 α -dihydrotestosterone regulation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 385-403. | 4.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 404 | Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 582587. | 3.5 | 22 |
| 405 | Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 249-263. | 1.6 | 4 |
| 406 | Targeting age-specific changes in CD4 ⁺ T cell metabolism ameliorates alloimmune responses and prolongs graft survival. <i>Aging Cell</i> , 2021, 20, e13299. | 6.7 | 16 |
| 407 | A glutamine "tug-of-war"™: targets to manipulate glutamine metabolism for cancer immunotherapy. <i>Immunotherapy Advances</i> , 2021, 1, Itab010. | 3.0 | 20 |
| 408 | Metabolic reprogramming in macrophage responses. <i>Biomarker Research</i> , 2021, 9, 1. | 6.8 | 227 |
| 409 | Targeting Cancer Metabolism and Current Anti-Cancer Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1286, 15-48. | 1.6 | 12 |
| 410 | Therapeutic Targeting of Glutamine Metabolism in Colorectal Cancer. , 2021, , 333-356. | | 0 |
| 411 | Metabolic control of cancer progression as novel targets for therapy. <i>Advances in Cancer Research</i> , 2021, 152, 103-177. | 5.0 | 5 |
| 412 | Glutamate is an essential mediator in glutamine-amplified insulin secretion. <i>Journal of Diabetes Investigation</i> , 2021, 12, 920-930. | 2.4 | 20 |
| 413 | 1-C Metabolism Serine, Glycine, Folates In Acute Myeloid Leukemia. <i>Pharmaceutics</i> , 2021, 14, 190. | 3.8 | 6 |
| 414 | Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery. <i>Pharmaceutics</i> , 2021, 13, 295. | 4.5 | 7 |
| 415 | Transporters at the Interface between Cytosolic and Mitochondrial Amino Acid Metabolism. <i>Metabolites</i> , 2021, 11, 112. | 2.9 | 21 |
| 416 | Linking Metabolic Reprogramming, Plasticity and Tumor Progression. <i>Cancers</i> , 2021, 13, 762. | 3.7 | 22 |
| 417 | Glutamine Synthetase as a Therapeutic Target for Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1701. | 4.1 | 28 |
| 418 | Systematic Identification of MACC1-Driven Metabolic Networks in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 978. | 3.7 | 4 |
| 419 | The Distinctive Serum Metabolomes of Gastric, Esophageal and Colorectal Cancers. <i>Cancers</i> , 2021, 13, 720. | 3.7 | 13 |
| 421 | Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1870. | 4.1 | 19 |
| 422 | DDIT3 Directs a Dual Mechanism to Balance Glycolysis and Oxidative Phosphorylation during Glutamine Deprivation. <i>Advanced Science</i> , 2021, 8, e2003732. | 11.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 423 | Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 336-344. | 1.7 | 16 |
| 424 | Architectural control of metabolic plasticity in epithelial cancer cells. <i>Communications Biology</i> , 2021, 4, 371. | 4.4 | 12 |
| 425 | CD44 modulates metabolic pathways and altered ROS-mediated Akt signal promoting cholangiocarcinoma progression. <i>PLoS ONE</i> , 2021, 16, e0245871. | 2.5 | 9 |
| 426 | A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 34 |
| 427 | Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells. <i>Scientific Reports</i> , 2021, 11, 9181. | 3.3 | 6 |
| 428 | Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness. <i>Cancer & Metabolism</i> , 2021, 9, 18. | 5.0 | 14 |
| 429 | Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior. <i>Scientific Reports</i> , 2021, 11, 8138. | 3.3 | 3 |
| 430 | Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4588-4611. | 6.4 | 22 |
| 431 | Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. <i>Cancer Letters</i> , 2021, 502, 180-188. | 7.2 | 35 |
| 432 | Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 667446. | 2.4 | 9 |
| 433 | Inhibition of guanosine monophosphate synthetase (<sc>GMPS</sc>) blocks glutamine metabolism and prostate cancer growth. <i>Journal of Pathology</i> , 2021, 254, 135-146. | 4.5 | 19 |
| 434 | Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio. <i>Frontiers in Oncology</i> , 2021, 11, 653621. | 2.8 | 7 |
| 435 | Targeting GLS1 to cancer therapy through glutamine metabolism. <i>Clinical and Translational Oncology</i> , 2021, 23, 2253-2268. | 2.4 | 28 |
| 436 | Metabolomics in cancer research and emerging applications in clinical oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 333-358. | 329.8 | 267 |
| 437 | Metabolic regulation in the immune response to cancer. <i>Cancer Communications</i> , 2021, 41, 661-694. | 9.2 | 23 |
| 438 | Mitochondrial metabolism-mediated redox regulation in cancer progression. <i>Redox Biology</i> , 2021, 42, 101870. | 9.0 | 40 |
| 439 | Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6262. | 4.1 | 53 |
| 440 | Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. <i>Cancer Letters</i> , 2021, 507, 80-88. | 7.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 441 | Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. <i>Cancers</i> , 2021, 13, 3230. | 3.7 | 17 |
| 442 | Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma. <i>Cancer & Metabolism</i> , 2021, 9, 27. | 5.0 | 11 |
| 443 | Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29188. | 1.5 | 7 |
| 444 | Local production of lactate, ribose phosphate, and amino acids by human triple-negative breast cancer. <i>Med</i> , 2021, 2, 736-754.e6. | 4.4 | 28 |
| 445 | CRISPR screens in physiologic medium reveal conditionally essential genes in human cells. <i>Cell Metabolism</i> , 2021, 33, 1248-1263.e9. | 16.2 | 77 |
| 447 | Inhibition of the γ -glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. <i>Cancer Letters</i> , 2021, 507, 13-25. | 7.2 | 20 |
| 448 | Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment. <i>Current Opinion in Chemical Biology</i> , 2021, 62, 64-81. | 6.1 | 39 |
| 449 | A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003. | 7.0 | 24 |
| 450 | Mitochondrial Metabolism in Carcinogenesis and Cancer Therapy. <i>Cancers</i> , 2021, 13, 3311. | 3.7 | 28 |
| 451 | Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7379. | 4.1 | 14 |
| 452 | Proline dehydrogenase in cancer: apoptosis, autophagy, nutrient dependency and cancer therapy. <i>Amino Acids</i> , 2021, 53, 1891-1902. | 2.7 | 12 |
| 453 | Amino acid metabolism as a therapeutic target in cancer: a review. <i>Amino Acids</i> , 2021, 53, 1169-1179. | 2.7 | 32 |
| 454 | Proteomics-based target identification of natural products affecting cancer metabolism. <i>Journal of Antibiotics</i> , 2021, 74, 639-650. | 2.0 | 10 |
| 455 | Coordination of the Uptake and Metabolism of Amino Acids in Mycobacterium tuberculosis-Infected Macrophages. <i>Frontiers in Immunology</i> , 2021, 12, 711462. | 4.8 | 5 |
| 456 | Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias. <i>Frontiers in Oncology</i> , 2021, 11, 694526. | 2.8 | 5 |
| 457 | The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 3963. | 3.7 | 8 |
| 459 | Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. <i>Cell Reports</i> , 2021, 36, 109617. | 6.4 | 18 |
| 460 | Mitochondria: The metabolic switch of cellular oncogenic transformation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188534. | 7.4 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 461 | Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy. <i>Trends in Cancer</i> , 2021, 7, 790-804. | 7.4 | 85 |
| 462 | Metabolic reprogramming in renal cancer: Events of a metabolic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188559. | 7.4 | 57 |
| 463 | Metabolic checkpoints and novel approaches for immunotherapy against cancer. <i>International Journal of Cancer</i> , 2022, 150, 195-207. | 5.1 | 7 |
| 464 | Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase. <i>Cell Death Discovery</i> , 2021, 7, 204. | 4.7 | 4 |
| 465 | More Than Meets the Eye Regarding Cancer Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9507. | 4.1 | 11 |
| 466 | Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells. <i>Cancer Cell International</i> , 2021, 21, 479. | 4.1 | 27 |
| 468 | Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection. <i>Cell and Bioscience</i> , 2021, 11, 176. | 4.8 | 6 |
| 469 | Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas. <i>Neuro-Oncology</i> , 2022, 24, 556-568. | 1.2 | 10 |
| 470 | Simple Esterification of [¹³ C]-Alpha-Ketoglutarate Enhances Membrane Permeability and Allows for Noninvasive Tracing of Glutamate and Glutamine Production. <i>ACS Chemical Biology</i> , 2021, 16, 2144-2150. | 3.4 | 6 |
| 471 | Quantitative modelling of amino acid transport and homeostasis in mammalian cells. <i>Nature Communications</i> , 2021, 12, 5282. | 12.8 | 42 |
| 472 | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 558-580. | 12.0 | 181 |
| 473 | Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells. <i>Cells</i> , 2021, 10, 2398. | 4.1 | 8 |
| 474 | Pharmacologic approaches to amino acid depletion for cancer therapy. <i>Molecular Carcinogenesis</i> , 2022, 61, 127-152. | 2.7 | 7 |
| 475 | Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177. | 0.7 | 12 |
| 476 | Cell-Specific Expression of Enzymes for Serine Biosynthesis and Glutaminolysis in Farm Animals. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1285, 17-28. | 1.6 | 12 |
| 477 | Mitochondria and Tumor Metabolic Flexibility: Mechanisms and Therapeutic Perspectives. , 2022, , 493-510. | | 1 |
| 478 | Glutamine Inhibition Reduces Iatrogenic Laryngotracheal Stenosis. <i>Laryngoscope</i> , 2021, 131, E2125-E2130. | 2.0 | 4 |
| 479 | Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas. <i>Disease Markers</i> , 2021, 2021, 1-9. | 1.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 480 | The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutation Research - Reviews in Mutation Research, 2021, 787, 108366. | 5.5 | 28 |
| 481 | MYC Regulation of Metabolism and Cancer. , 2015, , 101-122. | | 1 |
| 482 | Kr-POK (ZBTB7c) regulates cancer cell proliferation through glutamine metabolism. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2017, 1860, 829-838. | 1.9 | 10 |
| 483 | Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation. Scientific Reports, 2020, 10, 2259. | 3.3 | 26 |
| 487 | The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. Molecular Cancer Therapeutics, 2021, 20, 500-511. | 4.1 | 58 |
| 488 | Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. Journal of Clinical Investigation, 2020, 130, 3865-3884. | 8.2 | 230 |
| 489 | Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. Journal of Clinical Investigation, 2015, 125, 2293-2306. | 8.2 | 319 |
| 490 | Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3313-3335. | 8.2 | 303 |
| 491 | Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. Journal of Clinical Investigation, 2017, 127, 1631-1645. | 8.2 | 72 |
| 492 | Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes. PLoS Biology, 2017, 15, e2002810. | 5.6 | 40 |
| 493 | Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition. PLoS ONE, 2014, 9, e115144. | 2.5 | 38 |
| 494 | Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 825-832. | 3.8 | 28 |
| 495 | Right on TARGET: glutamine metabolism in cancer. Oncoscience, 2015, 2, 681-683. | 2.2 | 13 |
| 496 | Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: a PET imaging and metabolomics-mass-spectrometry study. Oncotarget, 2016, 7, 52017-52031. | 1.8 | 11 |
| 497 | Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells. Oncotarget, 2016, 7, 54691-54701. | 1.8 | 22 |
| 498 | Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget, 2016, 7, 53628-53641. | 1.8 | 26 |
| 499 | Structural basis for exploring the allosteric inhibition of human kidney type glutaminase. Oncotarget, 2016, 7, 57943-57954. | 1.8 | 39 |
| 500 | Selenite inhibits glutamine metabolism and induces apoptosis by regulating GLS1 protein degradation via APC/C-CDH1 pathway in colorectal cancer cells. Oncotarget, 2017, 8, 18832-18847. | 1.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 501 | Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer. <i>Oncotarget</i> , 2017, 8, 42664-42672. | 1.8 | 37 |
| 502 | Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 44171-44185. | 1.8 | 41 |
| 503 | Targeted inhibition of glutaminase as a potential new approach for the treatment of <i>NF1</i> associated soft tissue malignancies. <i>Oncotarget</i> , 2017, 8, 94054-94068. | 1.8 | 26 |
| 504 | A natural inhibitor of kidney-type glutaminase: a withanolide from <i>Physalis pubescens</i> with potent anti-tumor activity. <i>Oncotarget</i> , 2017, 8, 113516-113530. | 1.8 | 15 |
| 505 | A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. <i>Oncotarget</i> , 2018, 9, 11071-11082. | 1.8 | 10 |
| 506 | Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 7619-7631. | 1.8 | 89 |
| 507 | Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 31997-32012. | 1.8 | 73 |
| 508 | Q-ing tumor glutaminase therapy. <i>Oncotarget</i> , 2015, 6, 38440-38441. | 1.8 | 3 |
| 509 | Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth. <i>Oncotarget</i> , 2016, 7, 1765-1776. | 1.8 | 53 |
| 510 | Glutaminase inhibition in renal cell carcinoma therapy. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 356-364. | 2.1 | 11 |
| 511 | Mitochondrial determinants of chemoresistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 634-646. | 2.1 | 11 |
| 512 | Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes. <i>Current Medicinal Chemistry</i> , 2020, 27, 5317-5339. | 2.4 | 26 |
| 513 | Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways. <i>Current Neuropharmacology</i> , 2017, 15, 620-636. | 2.9 | 13 |
| 514 | Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2189-2200. | 4.0 | 21 |
| 515 | Convergence of Cancer Metabolism and Immunity: an Overview. <i>Biomolecules and Therapeutics</i> , 2018, 26, 4-9. | 2.4 | 24 |
| 516 | Imaging Cancer Metabolism. <i>Biomolecules and Therapeutics</i> , 2018, 26, 81-92. | 2.4 | 31 |
| 517 | Targeting metabolism in breast cancer: How far we can go?. <i>World Journal of Clinical Oncology</i> , 2016, 7, 122. | 2.3 | 48 |
| 518 | Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome. <i>Theranostics</i> , 2020, 10, 5736-5748. | 10.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 519 | A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. <i>ELife</i> , 2020, 9, . | 6.0 | 98 |
| 520 | Identification and characterization of a novel glutaminase inhibitor. <i>FEBS Open Bio</i> , 2022, 12, 163-174. | 2.3 | 10 |
| 521 | Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 676562. | 2.8 | 10 |
| 522 | Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. <i>Molecular and Cellular Oncology</i> , 0, , 00-00. | 0.7 | 0 |
| 523 | How to Identify Suitable Molecular Imaging Biomarkers. , 2017, , 163-176. | | 0 |
| 524 | Cancer Metabolism. , 2018, , 129-154. | | 0 |
| 526 | Metabolic Plasticity of IDH1- Mutant Glioma Cell Lines Is Responsible for Low Sensitivity to Glutaminase Inhibition. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 1 |
| 527 | Role of Mitochondria in Pancreatic Metabolism, Diabetes, and Cancer. , 2019, , 71-94. | | 0 |
| 530 | Glutamate in cancers: from metabolism to signaling. <i>Journal of Biomedical Research</i> , 2020, 34, 260. | 1.6 | 43 |
| 532 | The breast cancer oncogene IKK μ coordinates mitochondrial function and serine metabolism. <i>EMBO Reports</i> , 2020, 21, e48260. | 4.5 | 6 |
| 534 | Recent Advances in Drug Development Targeting Cancer Metabolism. , 2020, , 103-126. | | 0 |
| 535 | Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2184, 233-263. | 0.9 | 1 |
| 536 | The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled. <i>Journal of Biological Chemistry</i> , 2020, 295, 1328-1337. | 3.4 | 6 |
| 539 | Metabolic Pathways of Eukaryotes and Connection to Cell Mechanics. <i>Biological and Medical Physics Series</i> , 2020, , 825-891. | 0.4 | 1 |
| 540 | Glutamine metabolism in the proliferation of GS-expression pituitary tumor cells. <i>Endocrine Connections</i> , 2020, 9, 223-233. | 1.9 | 5 |
| 541 | The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. <i>PLoS ONE</i> , 2021, 16, e0259241. | 2.5 | 22 |
| 542 | Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 4265-4277. | 0.0 | 30 |
| 543 | Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy. <i>Cancers</i> , 2021, 13, 5912. | 3.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 544 | DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. <i>Communications Biology</i> , 2021, 4, 1289. | 4.4 | 30 |
| 546 | Identification of a Six-Gene Prognostic Signature Characterized by Tumor Microenvironment Immune Profiles in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 722421. | 2.3 | 4 |
| 547 | Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 615-627. | 6.4 | 10 |
| 548 | High-Throughput Screening Reveals New Glutaminase Inhibitor Molecules. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1849-1866. | 4.9 | 3 |
| 549 | Targeting cancer metabolism in the era of precision oncology. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 141-162. | 46.4 | 385 |
| 550 | A Non-Canonical Convergence of Carbohydrate and Glutamine Metabolism is Required After Metabolic Rewiring in a Solid Environment. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 551 | PPAR Ligands Induce Antiviral Effects Targeting Perturbed Lipid Metabolism during SARS-CoV-2, HCV, and HCMV Infection. <i>Biology</i> , 2022, 11, 114. | 2.8 | 14 |
| 552 | Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer. <i>Life Sciences</i> , 2022, 291, 120274. | 4.3 | 4 |
| 553 | Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap. <i>Cancers</i> , 2022, 14, 553. | 3.7 | 40 |
| 554 | Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. <i>Advances in Cancer Research</i> , 2022, 153, 267-304. | 5.0 | 2 |
| 555 | Radiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system x _C ^{sup} in tumors. <i>Theranostics</i> , 2022, 12, 1921-1936. | 10.0 | 9 |
| 557 | Self-Assembled Micellar Glutaminase Allosteric Inhibitor for Effective Therapeutic Intervention. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 213-225. | 6.7 | 2 |
| 558 | Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100512. | 1.7 | 15 |
| 559 | Clinical development of metabolic inhibitors for oncology. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 59 |
| 560 | Loss of glucose 6-phosphate dehydrogenase function increases oxidative stress and glutaminolysis in metastasizing melanoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, . | 7.1 | 35 |
| 561 | High-resolution structures of mitochondrial glutaminase C tetramers indicate conformational changes upon phosphate binding. <i>Journal of Biological Chemistry</i> , 2022, 298, 101564. | 3.4 | 9 |
| 562 | New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography. <i>Journal of Biological Chemistry</i> , 2022, 298, 101535. | 3.4 | 21 |
| 563 | Bioenergetic Metabolism In Osteoblast Differentiation. <i>Current Osteoporosis Reports</i> , 2022, 20, 53-64. | 3.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 564 | Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives. <i>Cells</i> , 2022, 11, 554. | 4.1 | 1 |
| 565 | Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment. <i>Diagnostics</i> , 2022, 12, 394. | 2.6 | 4 |
| 566 | Connections between metabolism and epigenetic modifications in cancer. <i>Medical Review</i> , 2021, 1, 199-221. | 1.2 | 7 |
| 567 | Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis. <i>Biochemical Pharmacology</i> , 2022, 198, 114943. | 4.4 | 15 |
| 568 | Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 48. | 4.1 | 40 |
| 569 | Defining the landscape of metabolic dysregulations in cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 345-362. | 3.3 | 8 |
| 570 | Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 902. | 3.7 | 39 |
| 571 | Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2246. | 4.1 | 8 |
| 572 | The critical function of metabolic reprogramming in cancer metastasis. <i>Aging and Cancer</i> , 2022, 3, 20-43. | 1.6 | 4 |
| 573 | Pharmacological Inhibition of Glutaminase 1 Attenuates Alkali-Induced Corneal Neovascularization by Modulating Macrophages. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19. | 4.0 | 5 |
| 574 | Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. <i>Scientific Reports</i> , 2022, 12, 5143. | 3.3 | 8 |
| 575 | Hypoxia Induces Saturated Fatty Acids Accumulation and Reduces Unsaturated Fatty Acids Independently of Reverse Tricarboxylic Acid Cycle in L6 Myotubes. <i>Frontiers in Endocrinology</i> , 2022, 13, 663625. | 3.5 | 3 |
| 576 | Metabolic Adaptations in an Endocrine-Related Breast Cancer Mouse Model Unveil Potential Markers of Tumor Response to Hormonal Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 786931. | 2.8 | 1 |
| 578 | Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. <i>Molecular Cell</i> , 2022, 82, 1821-1835.e6. | 9.7 | 22 |
| 579 | Glutamate blunts cell-killing effects of neutrophils in tumor microenvironment. <i>Cancer Science</i> , 2022, 113, 1955-1967. | 3.9 | 6 |
| 580 | Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114337. | 5.5 | 4 |
| 581 | Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112844. | 5.6 | 5 |
| 582 | Inhibition of glutaminase 1-mediated glutaminolysis improves pathological cardiac remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H749-H761. | 3.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 583 | Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 393. | 8.6 | 17 |
| 584 | Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification. <i>Biology</i> , 2021, 10, 1267. | 2.8 | 5 |
| 585 | The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers. <i>Current Cancer Drug Targets</i> , 2022, 22, 169-179. | 1.6 | 3 |
| 586 | Mitochondrial glutamine metabolism regulates sensitivity of cancer cells after chemotherapy via amphiregulin. <i>Cell Death Discovery</i> , 2021, 7, 395. | 4.7 | 7 |
| 587 | Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids. <i>Nutrition and Cancer</i> , 2022, 74, 2607-2621. | 2.0 | 4 |
| 588 | Metabolic response to radiation therapy in cancer. <i>Molecular Carcinogenesis</i> , 2022, 61, 200-224. | 2.7 | 3 |
| 589 | Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications. <i>Biomolecules</i> , 2022, 12, 580. | 4.0 | 35 |
| 590 | Preclinical studies for improving radiosensitivity of non-small cell lung cancer cell lines by combining glutaminase inhibition and senolysis. <i>Translational Oncology</i> , 2022, 21, 101431. | 3.7 | 2 |
| 602 | Zeolitic imidazolate framework-based nanoparticles for the cascade enhancement of cancer chemodynamic therapy by targeting glutamine metabolism. <i>Nanoscale</i> , 2022, 14, 8727-8743. | 5.6 | 9 |
| 603 | Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis. <i>Cells</i> , 2022, 11, 1471. | 4.1 | 6 |
| 604 | Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. <i>Cell Metabolism</i> , 2022, 34, 874-887.e6. | 16.2 | 55 |
| 605 | Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics. <i>Pharmaceutics</i> , 2022, 14, 997. | 4.5 | 19 |
| 606 | Targeting allosteric regulation of cancer metabolism. <i>Nature Chemical Biology</i> , 2022, 18, 441-450. | 8.0 | 14 |
| 607 | CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5479. | 4.1 | 21 |
| 608 | Targeting Energy Metabolism in Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5572. | 4.1 | 6 |
| 609 | Ginsenoside CK induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism. <i>Biochemical Pharmacology</i> , 2022, 202, 115101. | 4.4 | 17 |
| 610 | Discovery of novel Glutaminase allosteric inhibitors through drug repurposing and comparative MMGB/PBSA and molecular dynamics simulation. <i>Computers in Biology and Medicine</i> , 2022, 146, 105669. | 7.0 | 3 |
| 611 | Î±-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting. <i>Cancers</i> , 2022, 14, 2983. | 3.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 612 | ¹⁸ F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models. <i>Journal of Nuclear Medicine</i> , 2023, 64, 131-136. | 5.0 | 4 |
| 613 | Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. <i>MBio</i> , 2022, 13, . | 4.1 | 17 |
| 614 | Loss of Vascular Endothelial Glutaminase Inhibits Tumor Growth and Metastasis, and Increases Sensitivity to Chemotherapy. <i>Cancer Research Communications</i> , 2022, 2, 694-705. | 1.7 | 3 |
| 615 | Glutamine addiction promotes glucose oxidation in triple-negative breast cancer. <i>Oncogene</i> , 2022, 41, 4066-4078. | 5.9 | 15 |
| 616 | Biology of macrophage fate decision: Implication in inflammatory disorders. <i>Cell Biology International</i> , 2022, 46, 1539-1556. | 3.0 | 7 |
| 617 | Targeting mitochondrial metabolism for precision medicine in cancer. <i>Cell Death and Differentiation</i> , 2022, 29, 1304-1317. | 11.2 | 71 |
| 618 | The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103757. | 4.4 | 8 |
| 619 | The role of branched chain amino acids metabolic disorders in tumorigenesis and progression. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113390. | 5.6 | 9 |
| 620 | GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 3209-3222. | 0.9 | 42 |
| 621 | The effect of rehabilitation exercise on the expression of glutaminase and cardiopulmonary remodeling in pulmonary hypertension. <i>Medicine in Novel Technology and Devices</i> , 2022, 15, 100157. | 1.6 | 0 |
| 622 | Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity. <i>International Journal of Biological Macromolecules</i> , 2022, 216, 768-778. | 7.5 | 11 |
| 623 | GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. <i>Cancer Research</i> , 2022, 82, 3223-3235. | 0.9 | 16 |
| 624 | Mechanism and application of nonessential amino acid deprivation associated with tumor therapy. , 2022, 1, . | | 2 |
| 625 | Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. <i>Cell Communication and Signaling</i> , 2022, 20, . | 6.5 | 55 |
| 626 | Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer. <i>Advanced Science</i> , 2022, 9, . | 11.2 | 15 |
| 627 | Metabolic reprogramming: A novel metabolic model for pulmonary hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, . | 2.4 | 3 |
| 628 | A practical guide for the analysis, standardization and interpretation of oxygen consumption measurements. <i>Nature Metabolism</i> , 2022, 4, 978-994. | 11.9 | 28 |
| 629 | Relationship between metabolic reprogramming and drug resistance in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 630 | Metabolic targeting of malignant tumors: a need for systemic approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2115-2138. | 2.5 | 2 |
| 631 | The mitochondrial enzyme <i>FAHD1</i> regulates complex <i>II</i> activity in breast cancer cells and is indispensable for basal <i>BT</i> cells <i>in vitro</i> . <i>FEBS Letters</i> , 2022, 596, 2781-2794. | 2.8 | 2 |
| 632 | Design, synthesis, and pharmacological evaluation of 2-(1-(1,3,4-thiadiazol-2-yl)piperidin-4-yl)ethan-1-ol analogs as novel glutaminase 1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114686. | 5.5 | 4 |
| 633 | The Role of Alternative Splicing in Cancer: Regulatory Mechanism, Therapeutic Strategy, and Bioinformatics Application. <i>DNA and Cell Biology</i> , 0, , . | 1.9 | 0 |
| 634 | ¹³ C metabolic flux analysis clarifies distinct metabolic phenotypes of cancer cell spheroid mimicking tumor hypoxia. <i>Metabolic Engineering</i> , 2022, 73, 192-200. | 7.0 | 1 |
| 635 | Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113585. | 5.6 | 1 |
| 636 | Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1 β pathways in MRL/lpr mice. <i>International Immunopharmacology</i> , 2022, 112, 109133. | 3.8 | 13 |
| 637 | Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets. <i>Translational Oncology</i> , 2022, 26, 101534. | 3.7 | 5 |
| 638 | Metabolic dysregulation in cancer progression. , 2022, , 1-39. | | 0 |
| 639 | Designing metabolic target-specific inhibitors for cancer therapy. , 2022, , 239-280. | | 0 |
| 640 | Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy. <i>Drug Metabolism Reviews</i> , 2022, 54, 386-400. | 3.6 | 5 |
| 641 | Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2 α -dependent glutaminolysis pathway. <i>Science Advances</i> , 2022, 8, . | 10.3 | 11 |
| 642 | Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis. <i>Cancer Research Communications</i> , 2022, 2, 1144-1161. | 1.7 | 9 |
| 643 | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10587. | 4.1 | 4 |
| 644 | Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells. <i>Frontiers in Pharmacology</i> , 0, 13, . | 3.5 | 8 |
| 645 | Harnessing the cyclization strategy for new drug discovery. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4309-4326. | 12.0 | 13 |
| 646 | Amino acid metabolism in primary bone sarcomas. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 2 |
| 647 | Vitamin D receptor (<i>VDR</i>) mRNA overexpression is associated with poor prognosis in breast carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2022, 103, 183. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 648 | Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer. <i>Sub-Cellular Biochemistry</i> , 2022, , 523-555. | 2.4 | 0 |
| 649 | Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer. <i>Sub-Cellular Biochemistry</i> , 2022, , 201-237. | 2.4 | 1 |
| 650 | Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. <i>Biomolecules</i> , 2022, 12, 1590. | 4.0 | 6 |
| 651 | Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity. <i>Cells</i> , 2022, 11, 3103. | 4.1 | 6 |
| 652 | Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. <i>Advanced Science</i> , 2022, 9, . | 11.2 | 7 |
| 653 | Targeting cellular metabolism in head and neck cancer precision medicine era: A promising strategy to overcome therapy resistance. <i>Oral Diseases</i> , 2023, 29, 3101-3120. | 3.0 | 5 |
| 654 | Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. <i>Cancer Communications</i> , 2023, 43, 42-74. | 9.2 | 9 |
| 655 | A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 775-786. | 12.0 | 3 |
| 657 | Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113923. | 5.6 | 7 |
| 658 | CD8+ T cell metabolic changes in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166565. | 3.8 | 0 |
| 659 | Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. <i>Journal of Translational Internal Medicine</i> , 2022, . | 2.5 | 2 |
| 660 | CRISPR Cas9-mediated ablation of pyruvate carboxylase gene in colon cancer cell line HT-29 inhibits growth and migration, induces apoptosis and increases sensitivity to 5-fluorouracil and glutaminase inhibitor. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 0 |
| 661 | Î±-ketoglutarate suppresses immediate early gene expression in cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2022, 637, 144-152. | 2.1 | 2 |
| 662 | Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group. <i>European Journal of Medicinal Chemistry</i> , 2023, 246, 115014. | 5.5 | 1 |
| 663 | Nutrient Transporters: New Molecular Targets for Triple Negative Breast Cancer in Type 2 Diabetics. , 2022, , . | | 0 |
| 664 | Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue. <i>ACS Medicinal Chemistry Letters</i> , 0, , . | 2.8 | 2 |
| 665 | Overview of Cancer Metabolism and Signaling Transduction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12. | 4.1 | 9 |
| 666 | Effects of metabolic cancer therapy on tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 667 | Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation. <i>Molecular Carcinogenesis</i> , 2023, 62, 438-449. | 2.7 | 3 |
| 668 | Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. <i>Molecular Therapy</i> , 2023, 31, 729-743. | 8.2 | 8 |
| 669 | Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15296. | 4.1 | 4 |
| 670 | In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. <i>Science Advances</i> , 2022, 8, . | 10.3 | 20 |
| 671 | The role of glutamine metabolism in castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2023, 25, 192. | 1.6 | 4 |
| 672 | FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, . | 4.4 | 3 |
| 673 | Novel insight into metabolic reprogramming in cancer radioresistance: A promising therapeutic target in radiotherapy. <i>International Journal of Biological Sciences</i> , 2023, 19, 811-828. | 6.4 | 4 |
| 674 | Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 3 |
| 675 | Tumor hypoxia: From basic knowledge to therapeutic implications. <i>Seminars in Cancer Biology</i> , 2023, 88, 172-186. | 9.6 | 21 |
| 676 | Metabolic reprogramming of glutamine involved in tumorigenesis, multidrug resistance and tumor immunity. <i>European Journal of Pharmacology</i> , 2023, 940, 175323. | 3.5 | 3 |
| 678 | MYC oncogenes as potential anticancer targets. , 2023, , 191-219. | | 2 |
| 680 | Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 87, 129266. | 2.2 | 1 |
| 681 | Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. <i>IScience</i> , 2023, 26, 106020. | 4.1 | 1 |
| 682 | An updated patent review of glutaminase inhibitors (2019-2022). <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 17-28. | 5.0 | 8 |
| 683 | Discovery of aminothiazole derivatives as a chemical scaffold for glutaminase inhibition. <i>Results in Chemistry</i> , 2023, 5, 100842. | 2.0 | 0 |
| 686 | Characterization of cell line with dedifferentiated GIST-like features established from cecal GIST of familial GIST model mice. <i>Pathology International</i> , 0, , . | 1.3 | 0 |
| 687 | Glutamine metabolism in breast cancer and possible therapeutic targets. <i>Biochemical Pharmacology</i> , 2023, 210, 115464. | 4.4 | 11 |
| 688 | Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 1540. | 3.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 689 | Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 9 |
| 690 | Role and therapeutic targeting of glutamine metabolism in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2023, 25, . | 1.8 | 0 |
| 691 | Amino acid metabolic reprogramming in tumor metastatic colonization. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 4 |
| 692 | Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer. <i>BMC Gastroenterology</i> , 2023, 23, . | 2.0 | 3 |
| 693 | Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. <i>Tomography</i> , 2023, 9, 657-680. | 1.8 | 3 |
| 694 | A novel Ionidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism. <i>Pharmacological Research</i> , 2023, 190, 106740. | 7.1 | 2 |
| 695 | Potential of Neuroinflammation-Modulating Strategies in Tuberculous Meningitis: Targeting Microglia. , 2023, . | | 3 |
| 696 | Nutrient Metabolisms in Cancer and Related Signaling Pathways. , 0, 36, 1318-1327. | | 0 |
| 697 | Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics. <i>European Journal of Medicinal Chemistry</i> , 2023, 252, 115306. | 5.5 | 3 |
| 698 | Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. <i>Cancers</i> , 2023, 15, 1936. | 3.7 | 6 |
| 699 | Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies. <i>Future Drug Discovery</i> , 2022, 4, . | 2.1 | 5 |
| 700 | The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications. <i>Molecular Diagnosis and Therapy</i> , 0, , . | 3.8 | 2 |
| 702 | New Platform for Label-Free, Proximal Cellular Pharmacodynamic Assays: Identification of Glutaminase Inhibitors Using Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry. <i>ACS Chemical Biology</i> , 2023, 18, 942-948. | 3.4 | 3 |
| 703 | RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, . | 17.1 | 4 |
| 704 | PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, . | 7.1 | 8 |
| 705 | Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 3 |
| 706 | Crosstalk between arginine, glutamine, and the branched chain amino acid metabolism in the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 2 |
| 707 | Diselenide Covalent Allosteric Inhibitors of Glutaminase with Strong <i>In Vivo</i> Anticancer Activity. <i>ACS Medicinal Chemistry Letters</i> , 0, , . | 2.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 708 | Identification of Some Glutamic Acid Derivatives with Biological Potential by Computational Methods. <i>Molecules</i> , 2023, 28, 4123. | 3.8 | 0 |
| 709 | Metabolomics in drug research and development: The recent advances in technologies and applications. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3238-3251. | 12.0 | 2 |
| 710 | Therapeutic strategies targeting metabolic characteristics of cancer cells. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 187, 104037. | 4.4 | 1 |
| 711 | Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 475-485. | 1.0 | 1 |
| 712 | Cellular redox homeostasis maintained by malic enzyme 2 is essential for MYC-driven T cell lymphomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, . | 7.1 | 6 |
| 713 | Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2023, 24, 1021-1035. | 3.0 | 2 |
| 714 | Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. <i>Cancer Research Communications</i> , 2023, 3, 1067-1077. | 1.7 | 2 |
| 716 | Critical role of antioxidant programs in enzalutamide-resistant prostate cancer. <i>Oncogene</i> , 2023, 42, 2347-2359. | 5.9 | 1 |
| 717 | Dietary Manipulation of Amino Acids for Cancer Therapy. <i>Nutrients</i> , 2023, 15, 2879. | 4.1 | 2 |
| 718 | Targeting Metabolic Vulnerabilities in Epstein-Barr Virus-Driven Proliferative Diseases. <i>Cancers</i> , 2023, 15, 3412. | 3.7 | 0 |
| 719 | Intrinsic and extrinsic factors determining natural killer cell fate: Phenotype and function. <i>Biomedicine and Pharmacotherapy</i> , 2023, 165, 115136. | 5.6 | 2 |
| 720 | Phytochemicals Modify the Action of Cancer Cells Mitochondrial Drug-Resistance Mechanism. , 2023, 2, 79-105. | | 0 |
| 722 | Role of mitochondrial alterations in human cancer progression and cancer immunity. <i>Journal of Biomedical Science</i> , 2023, 30, . | 7.0 | 6 |
| 723 | Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 93, 129438. | 2.2 | 0 |
| 724 | Glutamine metabolic reprogramming in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, . | 3.5 | 4 |
| 725 | YAP governs cellular adaptation to perturbation of glutamine metabolism by regulating ATF4-mediated stress response. <i>Oncogene</i> , 2023, 42, 2828-2840. | 5.9 | 2 |
| 726 | Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320. <i>Future Medicinal Chemistry</i> , 0, , . | 2.3 | 0 |
| 727 | Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 600-615. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 728 | Participation of protein metabolism in cancer progression and its potential targeting for the management of cancer. <i>Amino Acids</i> , 2023, 55, 1223-1246. | 2.7 | 2 |
| 729 | Metabolic Alterations in Canine Mammary Tumors. <i>Animals</i> , 2023, 13, 2757. | 2.3 | 0 |
| 730 | Advances of SIRT4 in cancer metabolism and therapy. , 2023, 1, . | | 0 |
| 731 | Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly. <i>World Journal of Gastroenterology</i> , 0, 29, 4499-4527. | 3.3 | 1 |
| 732 | The Illustration of Altered Glucose Dependency in Drug-Resistant Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13928. | 4.1 | 1 |
| 733 | Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism. <i>Antioxidants</i> , 2023, 12, 1818. | 5.1 | 0 |
| 734 | Tumor microenvironmental nutrients, cellular responses, and cancer. <i>Cell Chemical Biology</i> , 2023, 30, 1015-1032. | 5.2 | 2 |
| 735 | Targeting the Subpocket Enables the Discovery of Thiadiazole- ϵ -Pyridazine Derivatives as Glutaminase C Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 1455-1466. | 2.8 | 0 |
| 736 | Glutaminase (GLS1) gene expression in primary breast cancer. <i>Breast Cancer</i> , 2023, 30, 1079-1084. | 2.9 | 0 |
| 737 | Advances in Research on the Relationship between Glutamine Metabolism and Breast Cancer. , 2023, 3, 1-3. | | 0 |
| 740 | Metabolic Analysis of DFO-Resistant Huh7 Cells and Identification of Targets for Combination Therapy. <i>Metabolites</i> , 2023, 13, 1073. | 2.9 | 0 |
| 741 | Structural basis for activation and filamentation of glutaminase. <i>Cell Research</i> , 0, , . | 12.0 | 0 |
| 742 | KEAP1/NRF2 Mutations in Stem Cells Define an Aggressive Subset of Head and Neck Cancer Patients Who Have a Poor Prognosis, Lung Metastasis, and Therapeutic Failure. <i>Cancers</i> , 2023, 15, 5006. | 3.7 | 0 |
| 743 | Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, . | 8.6 | 1 |
| 744 | Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. <i>Scientific Reports</i> , 2023, 13, . | 3.3 | 0 |
| 745 | Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study. <i>BMC Cancer</i> , 2023, 23, . | 2.6 | 0 |
| 746 | Development, Optimization, and Evaluation of Nano-platforms for Delivery of siRNA and BPTES in c-Myc Induced Breast Cancer. <i>Journal of Pharmaceutical Innovation</i> , 2023, 18, 2210-2234. | 2.4 | 0 |
| 747 | The immunometabolic ecosystem in cancer. <i>Nature Immunology</i> , 2023, 24, 2008-2020. | 14.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 748 | Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress. <i>Blood Advances</i> , 0, , . | 5.2 | 0 |
| 749 | Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade. <i>Journal of Controlled Release</i> , 2024, 365, 480-490. | 9.9 | 2 |
| 751 | Glutaminase inhibition as potential cancer therapeutics: current status and future applications. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2024, 39, . | 5.2 | 1 |
| 753 | Glutamine addiction in tumor cell: oncogene regulation and clinical treatment. <i>Cell Communication and Signaling</i> , 2024, 22, . | 6.5 | 1 |
| 755 | Design strategies and recent development of bioactive modulators for glutamine transporters. <i>Drug Discovery Today</i> , 2024, 29, 103880. | 6.4 | 0 |
| 756 | Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2024, 67, 988-1007. | 6.4 | 0 |
| 758 | Influence of glutamine metabolism on diabetes Development:A scientometric review. <i>Heliyon</i> , 2024, 10, e25258. | 3.2 | 0 |
| 759 | Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3 β / β -catenin/EMT pathway. <i>Cancer Letters</i> , 2024, 586, 216653. | 7.2 | 0 |
| 761 | Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle. <i>European Journal of Medicinal Chemistry</i> , 2024, 268, 116234. | 5.5 | 0 |
| 762 | Glutaminase potentiates the glycolysis in esophageal squamous cell carcinoma by interacting with PDK1. <i>Molecular Carcinogenesis</i> , 2024, 63, 897-911. | 2.7 | 0 |
| 763 | Fumarate induces LncRNA-MIR4435-2HG to regulate glutamine metabolism remodeling and promote the development of FH-deficient renal cell carcinoma. <i>Cell Death and Disease</i> , 2024, 15, . | 6.3 | 0 |
| 764 | Thermally annealed large-scale gold nanostructure platform for long-term and label-free electrochemical monitoring of cellular metabolism. <i>Chemical Engineering Journal</i> , 2024, 485, 149864. | 12.7 | 0 |
| 767 | A redox-responsive prodrug for tumor-targeted glutamine restriction. <i>Journal of Controlled Release</i> , 2024, 368, 251-264. | 9.9 | 0 |
| 768 | Filament formation drives catalysis by glutaminase enzymes important in cancer progression. <i>Nature Communications</i> , 2024, 15, . | 12.8 | 0 |
| 769 | Exploiting the Achilles's™ heel of cancer: disrupting glutamine metabolism for effective cancer treatment. <i>Frontiers in Pharmacology</i> , 0, 15, . | 3.5 | 0 |
| 770 | A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. <i>Journal of Experimental and Clinical Cancer Research</i> , 2024, 43, . | 8.6 | 0 |
| 771 | Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism. <i>Metabolites</i> , 2024, 14, 170. | 2.9 | 0 |
| 772 | Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, . | 17.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 773 | Prognostic Signature in Osteosarcoma Based on Amino Acid Metabolism-Associated Genes. Cancer Biotherapy and Radiopharmaceuticals, 0, , . | 1.0 | 0 |
| 774 | Inhibition of glutamine metabolism increases sensitivity to plasma-activated medium-induced cytotoxicity. Free Radical Research, 2024, 58, 170-179. | 3.3 | 0 |